Business Description

Fresenius Medical Care AG
NAICS : 621492
SIC : 8092
ISIN : DE0005785802
Share Class Description:
XTER:FME: Ordinary SharesCompare
Compare
Traded in other countries / regions
FME.GermanyFMS.USA0H9X.UKFME.Austria1FME.ItalyFMSC34.BrazilFME N.Mexico Index Membership
STOXX Europe 600DAX 30iShares MSCI ACWI Ex US Index FundDAX 30 IPO Date
1996-10-02Description
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.14 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.75 | |||||
Debt-to-EBITDA | 4.64 | |||||
Interest Coverage | 4.1 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1.83 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.1 | |||||
3-Year EBITDA Growth Rate | -3.4 | |||||
3-Year EPS without NRI Growth Rate | -13.3 | |||||
3-Year FCF Growth Rate | 1 | |||||
3-Year Book Growth Rate | 4.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 24.94 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.05 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 69.49 | |||||
9-Day RSI | 55.28 | |||||
14-Day RSI | 51.64 | |||||
3-1 Month Momentum % | 9.02 | |||||
6-1 Month Momentum % | 13.27 | |||||
12-1 Month Momentum % | 39.41 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.46 | |||||
Quick Ratio | 1.08 | |||||
Cash Ratio | 0.27 | |||||
Days Inventory | 52.99 | |||||
Days Sales Outstanding | 68.27 | |||||
Days Payable | 20.63 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.98 | |||||
Dividend Payout Ratio | 0.5 | |||||
3-Year Dividend Growth Rate | -3.9 | |||||
Forward Dividend Yield % | 2.98 | |||||
5-Year Yield-on-Cost % | 2.94 | |||||
Shareholder Yield % | 12.48 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 24.45 | |||||
Operating Margin % | 8.38 | |||||
Net Margin % | 3.17 | |||||
EBITDA Margin % | 11.96 | |||||
FCF Margin % | 9.42 | |||||
ROE % | 4.39 | |||||
ROA % | 1.85 | |||||
ROIC % | 3.71 | |||||
3-Year ROIIC % | 24.98 | |||||
ROC (Joel Greenblatt) % | 21.45 | |||||
ROCE % | 5.62 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat score | 7 | |||||
Tariff score | 5 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 23.02 | |||||
Forward PE Ratio | 12.83 | |||||
PE Ratio without NRI | 20.56 | |||||
Shiller PE Ratio | 11.88 | |||||
Price-to-Owner-Earnings | 109.17 | |||||
PS Ratio | 0.73 | |||||
PB Ratio | 1 | |||||
Price-to-Free-Cash-Flow | 7.8 | |||||
Price-to-Operating-Cash-Flow | 5.91 | |||||
EV-to-EBIT | 15.89 | |||||
EV-to-Forward-EBIT | 11.76 | |||||
EV-to-EBITDA | 10.57 | |||||
EV-to-Forward-EBITDA | 7.15 | |||||
EV-to-Revenue | 1.26 | |||||
EV-to-Forward-Revenue | 1.22 | |||||
EV-to-FCF | 13.42 | |||||
Price-to-GF-Value | 1.27 | |||||
Price-to-Projected-FCF | 0.49 | |||||
Price-to-Median-PS-Value | 0.63 | |||||
Earnings Yield (Greenblatt) % | 6.29 | |||||
FCF Yield % | 12.95 | |||||
Forward Rate of Return (Yacktman) % | 1.32 |